ReviewEndocrine, metabolic & immune disorders drug targets2026
Living with PCOS: A Narrative of its Biology, Diagnosis, and Evolving Treatment.
Review in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Female Serum HER2 Expression: Its Association With Metabolic Syndrome and Treatment Drug Response.International journal of endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPolycystic ovary syndrome (PCOS) is a complex endocrine disorder characterized by hyperandrogenism, ovarian dysfunction, and metabolic abnormalities. It affects between 4% and 21% of females of fertile age. The present review provides a comprehensive analysis of PCOS, covering pathophysiology, diagnostic criteria, prevalence, biochemical markers, and demographic influences. It examines genetic, hormonal, and lifestyle variables, contributing to the conditions, highlighting ethnic disparities in prevalence.
methodsTo systematically analyse current data and refine evidence-based diagnosis and management guidelines, published in 2018, a global team was assembled. A systematic literature search was conducted across major academic databases, including PubMed, Scopus, Web of Science, and Google Scholar, to identify relevant studies on PCOS pathophysiology, diagnosis, and emerging therapies. Based on the global team's view, our generalised narrative review explores metabolic implications such as glucose intolerance, obesity, and type-2 diabetes, as well as hormonal imbalances involving androgens, luteinizing hormone, and prolactin.
resultsLifestyle factors, socioeconomic status, and ethnicity significantly influenced PCOS expression. Advancements in diagnosis, including AI-driven evaluation and precision medicine approaches, are discussed, alongside improvements in biochemical testing and treatment strategies. DISCUSSION: PCOS expression varies by lifestyle, ethnicity, and socioeconomic status. Emerging diagnostics like AI and precision medicine enhance detection, treatment, and understanding of its metabolic complexity.
conclusionThe review emphasizes the importance of personalized interventions and integrated healthcare approaches to enhance PCOS management and patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.